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1 
Clonal expansion of community-associated methicillin-resistant 1 
Staphylococcus aureus in people who inject drugs from 2012 to 2017: 2 
prevalence, risk factors and molecular epidemiology  3 
Abstract 4 
Introduction 5 
In 2015, Bristol (South West England) experienced a large increase in cases of methicillin-resistant 6 
Staphylococcus aureus (MRSA) infection in people who inject drugs (PWID). We characterised and 7 
estimated the prevalence of MRSA colonisation among PWID in Bristol and tested evidence of a 8 
clonal outbreak using whole-genome sequencing (WGS). 9 
Methods 10 
PWID recruited through an unlinked-anonymous community survey during 2016 completed 11 
behavioural questionnaires and were screened for MRSA. Univariable logistic regression examined 12 
associations with MRSA colonisation. Phylogenetic analysis used lineage-matched MRSA isolates, 13 
comparing PWID (screening and retrospective bacteraemia samples) with non-PWID (Bristol 14 
screening) in Bristol, and national reference laboratory database samples. 15 
Results 16 
The MRSA colonisation prevalence was 8.7% (13/149) and was associated with frequently injecting 17 
in public places(OR:5.5, 95%CI:1.34-22.70), recent healthcare contact (4.3, 95%CI:1.34-13.80) and 18 
injecting in groups of three or more (15.8, 95%CI:2.51-99.28). People reporting any one of: injecting 19 
in public places, injection site skin and soft tissue infection or hospital contact accounted for 12/13 20 
MRSA positive cases (sensitivity 92.3%; specificity 51.5%). Phylogenetic analysis identified a 21 
dominant clade associated with infection and colonisation among PWID in Bristol belonging to ST5-22 
SCCmecIVg. 23 
2 
Conclusions  1 
This is the first study to combine WGS and epidemiological data to investigate an increase in MRSA 2 
among PWID. MRSA colonisation in Bristol PWID is substantially elevated compared to general 3 
population estimates (<0.1%-1.5%) and there is evidence of clonal expansion, community-based 4 
transmission and increased infection risk related to the colonising strain. Targeted interventions, 5 
including community screening and suppression therapy, education and basic infection control are 6 
needed to reduce MRSA infections in PWID. 7 
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Introduction  2 
Methicillin-resistant Staphylococcus aureus (MRSA) can exist as a harmless commensal or a potentially life-3 
threatening pathogen [1, 2]. Clinical presentations range from localised skin and soft tissue infections (SSTIs) to 4 
disseminated blood stream infections. These infections are responsible for substantial healthcare costs, morbidity 5 
and mortality [2–4]. The UK government and othrs have adopted a zero tolerance approach to avoidable healthcare 6 
associated infections with a focus on MRSA bacteraemia [5, 6]. However this approach is controversial as organisms 7 
can be introduced through multiple independent sources [5].  8 
MRSA can survive in a range of ecological settings, interact with and colonise the human host and develop 9 
antimicrobial resistance via a range of mechanisms [4]. These traits allow MRSA to spread between populations and 10 
species exploiting niches and opening up footholds to establish reservoirs within different settings [4]. MRSA was 11 
initially thought to be confined to healthcare settings (HA-MRSA) but during the 1980s infections became apparent 12 
in the community (CA-MRSA) and in the early 2000’s were also identified in humans associated with exposure to 13 
livestock (LA-MRSA) [1, 7]. Colonising MRSA can be transmitted from person-to-person and introduced into the body 14 
when host defences are breached [1, 8, 9]. This is apparent in communities of people who inject drugs (PWID) with 15 
outbreaks previously reported in England and the USA resulting in substantial morbidity and mortality [10–12]. 16 
Studies in Switzerland (2001), Canada (2006) and USA (2012) have found a high MRSA colonisation prevalence in 17 
PWID ranging from 5.7-18.6% [10, 11, 13]. These high prevalence estimates contrast sharply with general population 18 
estimates of <0.1% - 1.5% and appear to be driven in part by frequent healthcare contact  [10, 13–18]. 19 
In the UK and Europe there is limited information on the incidence of infection and prevalence of colonisation 20 
associated with MRSA in PWID. It has been shown that symptoms of probable SSTI at injection sites  are common, 21 
with 36% of PWID reporting these in a national survey in 2016 [19, 20]. These reports, however, are not laboratory 22 
confirmed and do not provide information on the aetiological agent.  Infections in PWID are often exacerbated 23 
through poor and delayed health-seeking behaviours. This results in more serious and difficult to treat infections and 24 
substantial costs [21].  For example,  in UK NHS costs from SSTI are estimated to be £15.5 to £77.0 million per annum 25 
(€17.4 to €86.2 million per annum) [19, 22].  26 
4 
Bristol is a city in the South West of England with a population of 459,000 and it is estimated that there are between 1 
1500 – 2700 persons injecting drugs. Bristol has the 2nd highest prevalence of crack use, 4th highest opiate use and 2 
the highest use crack and opiates in combination (snowballing) (data not shown).  The UK City of Bristol saw a large 3 
increase in laboratory reports of MRSA infections in people with injecting risk factors. An increase in MRSA 4 
bacteraemia occurring in PWID was detected through the post infection review process and prompted further 5 
investigation This found Infections in PWID to be a growing proportion of all MRSA cases reported in Bristol with the 6 
number more than doubling from 19 in 2013 to 45 in 2014,this increase was sustained in 2015 (46 infections) and up 7 
to August 2016 (37 infections) (data not shown).  Infections in PWID were often serious with a considerable number 8 
resulting in protracted hospital admissions, amputations and/or death. Between January 2014 and August 2016, 18% 9 
of all reported infections in PWID were bloodstream infections (data not shown). This increase in MRSA among PWID 10 
in Bristol is in contrast to the national decline in MRSA bacteraemia rates over the past ten years [23]. Only MRSA 11 
bacteraemia samples were routinely sent for typing and there was no information on colonisation within the 12 
community.  We therefore aimed to estimate the prevalence of MRSA among PWID in Bristol, explore the genetic 13 
relatedness of these samples compared to other PWID MRSA bacteraemia isolates and non-PWID isolates, identify 14 
injecting and non-injecting risk factors associated with infection, and provide evidence to inform development 15 
and/or implementation of population specific control interventions.  16 
Methods  17 
Study population 18 
In 2016 a cross-sectional survey of PWID living in the City of Bristol was undertaken in partnership with the national 19 
Unlinked Anonymous Monitoring (UAM) survey of PWID [24]. The UAM has been running since 1990 and is an 20 
annual cross-sectional survey that recruits PWID from across England, Wales and Northern Ireland. The 21 
methodological details have been reported previously [25, 26].   22 
PWID in the City of Bristol were recruited through fixed site and mobile needle and syringe programme (NSP) using 23 
non-probability quota sampling [27]. The sample was purposely recruited to reflect age and sex data held by Bristol 24 
Drugs Project (BDP). BDP are a charity that provide drug and alcohol services within the City of Bristol. The study 25 
received ethical approval from the London research ethics committee (REC reference: 98/2/051).  26 
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5 
Data collection 1 
Recruited participants completed an expanded version of the UAM questionnaire which had been piloted on a group 2 
of BDP service users. This collected information on age and sex, homelessness, prior imprisonment, psychoactive 3 
drug use, uptake of health services and sexual behaviours and published in 2017 [28]. Questions were added 4 
according to a priori hypotheses relating to MRSA colonisation: living conditions (accommodation type, access to 5 
running water and living arrangements), injecting practice (injection site and physical location), and person to person 6 
contact (numbers of injecting companions) and previous infections (SSTI and MRSA). Data were double entered from 7 
paper questionnaires into a validated Epidata v3.1 data collection form [29]. Data inconsistencies were checked 8 
against original paper forms. Data were cleaned and recoded using R v3.2.0 [30].  9 
Data analysis 10 
People were excluded from the analysis if they did not report injecting in the past year or if they had previously 11 
completed the UAM survey in that year. We identified factors associated with MRSA colonisation using univariable 12 
logistic regression and calculated odds ratios (OR) and corresponding 95% confidence intervals (CI).  13 
We defined groups of people at greater chance of colonisation by examining combinations of risk factors chosen 14 
based upon the univariable analysis (OR > 2.5) and potential for targeting interventions. Factors representing recent 15 
MRSA colonisation were excluded. Risk factor combinations were assessed in terms of sensitivity, specificity, receiver 16 
operator curve (ROC) and positive predictive value. A ROC value of 0.70 or above was used as a threshold for 17 
inclusion [31].  18 
Microbiological testing  19 
Trained BDP staff members collected groin and nasal swabs from participants. Swabs were cultured onto Brilliance 20 
Staph 24 agar (Oxoid). Presumptive S.aureus were initially identified using matrix-assisted laser desorption 21 
ionization-time of flight mass spectrometry MALDI-TOF (Bruker Daltonik GmbH, Germany) and MRSA were identified 22 
by antibiotic susceptibility testing using VITEK 2 (software v07.01 and card name AST-P635, bioMérieux). Colonised 23 
participants were defined as people living in the City of Bristol who reported injecting within the last past year and 24 
found to be positive for MRSA colonisation in nasal and/or groin sites.  25 
Whole-genome sequence analysis Phylogenetic analysis 26 
6 
 All MRSA were subjected to WGS, bioinformatic and phylogenetic analysis as described previously, with N315 1 
(NC002745) being used as reference [32] . Briefly, genomic DNA was extracted using the QIAsymphony platform 2 
(Qiagen), fragmented and tagged for multiplexing with Nextera XT DNA Sample Preparation Kits, followed by paired-3 
end sequencing on an Illumina HiSeq 2500 platform to produce 100 bp paired-end reads (Illumina, Cambridge, UK) 4 
and a coverage above 30x [32]. For phylogenetic analysis, sequence reads were mapped to the N315 reference strain 5 
(NC002745) using BWA(0.7.5). SNPs were called using GATK2.6.5. Genetic relatedness was determined using only 6 
high quality SNPs (AD genotype = 0.9). Coverage was above 95% of the reference genome. SNPs were concatenated 7 
and aligned allowing 20% of Ns and gaps. 8 
Bristol PWID colonisation isolates identified as belonging to a dominant MRSA clone were compared with lineage-9 
matched isolates that had been subjected to WGS in PHE, specifically (i) retrospective Bristol PWID MRSA 10 
bacteraemia isolates, (ii) non-PWID MRSA carriage isolates from pre-admission screening swabs from the University 11 
Hospital Bristol (UHB) and (iii) contemporaneous representative MRSA from the PHE national reference laboratory 12 
archive.  Susceptibility data were not available for these comparator isolates. The retrospective Bristol PWID 13 
bacteraemia isolates were identified through record linkage between drug services data and laboratory reports of all 14 
samples processed at UHB laboratory from 2012 to 2016. Repeat, non-duplicate, infections were included and 15 
defined as any MRSA with a sample date greater than 14 days apart. Non-PWID UHB admission screening samples 16 
were selected from a convenience sample of MRSA positive UHB admission screening samples collected during 17 
October 2016. This time period was contemporaneous with the PWID swabbing element of the study. Details of the 18 
UHB screening criteria have been described previously [33].  These were checked against hospital records to ensure 19 
they were from people not reporting injecting drug use. PHE national reference laboratory archive isolates had 20 
information on the geographical location and presence of injecting risk factors collated.  21 
Clusters were defined by hierarchical clustering using single linkage and Single Nucleotide Polymorphism (SNP) 22 
threshold of 150 using fastcluster in R (Supplementary Table 2).   [34]. Phylogeny was inferred from concatenated 23 
SNP alignment by using RaxML (Maximum Likelihood using GTR substitution model and 100 bootstrap) [35]. The tree 24 
was visualised using iTOL and pairwise SNP distance matrix was calculated excluding Ns and gaps (Supplementary 25 
Table 1). 26 
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Descriptive statistics, frequencies and percentages, were used to compare epidemiological characteristics of people 1 
within and between clusters.  2 
Results  3 
Study population 4 
There were 153 survey participants of which 149 reported injecting in the past year and were included in the 5 
analysis. The majority of participants were male (84%, 128/153) and were aged between 35 and 44 years (46%, 6 
71/153). The median age was similar for men (39, IQR: 34.5–46) and women (40, IQR:  31–45). The majority (95%, 7 
142/149) reported injecting in the past month, commonly with opioids (35%, 50/142) or opioids and stimulant 8 
combinations (30%, 42/142). Participants typically reported injecting into their arms (56%, 79/142) and/or groin 9 
(52%, 74/142); 44% (65/149) reported homelessness within the past year. Over a third (37%, 47/142) of people self-10 
reported symptoms of a previous SSTI at their injection site in the past year. 11 
A total of 13 people were colonised with MRSA, giving a prevalence of 8.7%. Twenty people reported a previous 12 
SSTI; 13 (10%, 13/136) in non-colonised and 6 (%, 6/13) in colonised people. Six colonised people (6/13) reported a 13 
previous SSTI due to MRSA. Four (4/6) of these occurred in the past 3 months and all reported being prescribed 14 
decolonisation therapy (nasal cream and body wash) in the past month.  In comparison, of the remaining 136 15 
participants, 17 (13%) reported a previous MRSA infection, five (29%) within the past 3 months and four (80%) were 16 
reported as SSTI and five (3.7%) reported previous decolonisation.  17 
Factors associated with MRSA colonisation 18 
We identified several factors strongly associated with MRSA colonisation among PWID in Bristol. Participants who 19 
reported most frequently injecting in public places (OR: 5.5, 95% CI: 1.34 to 22.70), hospital contact in the past 20 
month (OR: 4.3, 95% CI: 1.34 to 13.80), most frequently injecting in a group of three or more (OR: 15.8, 95% CI: 2.51 21 
to 99.28) and experiencing an MRSA infection in the past 3 months (OR: 13.6, 95% CI: 2.98 to 62.17) were associated 22 
with MRSA colonisation. Weaker, non-significant, associations were identified for SSTI at an injecting site in past year 23 
(OR: 2.8, 95% CI: 0.89 to 8.85), homelessness in the past year (OR: 3.2, 95% CI: 0.94 to 10.96), groin injecting (OR: 24 
3.8, 95% CI: 0.99 to 14.23) and previous deep vein thrombosis (DVT) comorbidity (OR: 2.6, 95% CI: 0.81 to 8.18), see 25 
table 1. 26 
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Six indicators met our criteria for grouping: injecting in public places, hospital contact, injecting in a group of three or 1 
more, SSTI, homelessness in the past year and groin injecting. We identified four groups according to different 2 
permutations of 4/6 indicator variables, which defined Bristol PWID with greater odds of MRSA colonisation with 3 
adequate sensitivity and specificity (ROC 0.7). Group 1 defined people who reported frequently injecting in public 4 
places or SSTI in past year or healthcare contact in past month. Group 2 people included people reporting injected in 5 
a group of three or more or frequently inject in public places or SSTI in past year or healthcare contact in past month. 6 
Group 3 included people with a SSTI in past year or healthcare contact in past month. Group 4 included people 7 
reporting injecting in a group of three or more or SSTI in past year or Healthcare contact in past month. Group one 8 
and two best explained MRSA colonisation accounting for 12/13 colonised participants with high sensitivity (>92%) 9 
and moderate specificity (>=50%), see table 2.   10 
Microbiological analysis 11 
In total, there were 16 Bristol PWID colonisation samples from our survey, 39 retrospective Bristol PWID 12 
bacteraemia samples, and 25 non-PWID UHB admission screening samples. The 16 Bristol PWID colonisation isolates 13 
were recovered from 13 survey participants and included two phenotypically distinct isolates from one participant 14 
and two who were positive at both nose and groin sites. Genomic analysis showed the majority of the Bristol PWID 15 
colonisation MRSA (12/16) belonged to multi-locus sequence type 5 (ST5), encoded staphylococcal cassette 16 
chromosome mec type IVg (SCCmecIVg) and were PVL negative. The remainder belonged to ST1-IV (n=3) or ST3919-17 
IV (n=1; a single locus variant of ST8). Greater heterogeneity was apparent among the non-PWID UHB admission 18 
screening samples with eight (32%) of 25 belonging to multi-locus sequence type clonal complex 5 (CC5); the 19 
remainder comprised CC22 (n=8), CC30 (n=4), CC1 (n=3), CC8 (n=1) and CC59 (n=1).  20 
A phylogenetic tree of 71 ST5 MRSA (24 bacteraemia and 12 carriage isolates from PWID in Bristol, 8 pre-admission 21 
screening swabs from UHB patients in Bristol and 27 from PHE national reference laboratory archives) is shown in 22 
Figure 1. The majority (68%; 48/71) belonged to a single lineage (ST5-SCCmecIVg) herein dubbed the “Bristol clade”.  23 
Within the Bristol clade, three sub-clades were apparent. Sub-clade A comprised four PWID carriage isolates 24 
recovered in 2016. There were nine isolates in sub-clade B, recovered over a four year period (2014-2017), 25 
comprising four carriage and three bacteraemia isolates from PWID in Bristol and two bacteraemia cases with 26 
injecting status unknown: one each from London and the South East. Sub-clade C was the largest and included 33 27 
9 
isolates recovered over six year period (2012-2017); 31 were from Bristol (25 PWID, the injecting status for the other 1 
six was unknown) and included 23 bacteraemia, four carriage and four non-invasive samples. The remaining two 2 
included one each from non-PWID in Wales and North West England. The remaining 23 isolates (namely, nationally 3 
representative CC5 comparator isolates including three from PWID in the East Midlands and three from non-PWID 4 
UHB admission screening samples) in the tree recovered over the same timescale (2012-2017) were phylogenetically 5 
heterogeneous; none of the Bristol PWID isolates were represented in this group. All were ST5 but none encoded 6 
SCCmecIVg, although multiple other SCCmec types were apparent and, in contrast to the Bristol clade, few resistance 7 
traits were identified, see figure one. The PWID carriage samples that were part of the Bristol clade varied in terms 8 
of their epidemiological metadata, see table 3.  9 
In addition to SCCmecIVg, other resistance elements were also highly conserved among the Bristol clade isolates; 10 
specifically, Tn554 which encodes ermA and ant(9)-Ia (conferring resistance to erythromycin and spectinomycin 11 
respectively) and mutational resistance to fluoroquinolones (grlA S80F). Loss of Tn554 was apparent in seven sub-12 
clade B isolates. Independent loss of this mobile element was observed in two sub-clade C isolates; a further two 13 
displayed mutational resistance to fusidic acid in an apparent single event (fusA V90I).  One isolate carrying 14 
mutational resistance (ileS V588F) exhibited intermediate resistance to mupirocin on VITEK. 15 
Discussion  16 
To our knowledge, this is the first study to have combined WGS and epidemiological data to provide novel insights 17 
into an increase in MRSA among PWID. This study was instigated due to a large increase in the number of MRSA 18 
infections in PWID in Bristol.  The MRSA colonisation prevalence among PWID in Bristol was around six times higher 19 
than  the general population (8.7% vs up to 1.5%) but is broadly in line with previous studies of MRSA colonisation 20 
among PWID (5.7-18.6%) [10, 13, 14, 16].  This puts Bristol PWID at increased risk due to the well-defined association 21 
between colonisation and infection [8]. The factors associated with MRSA colonisation were PWID who reported 22 
injecting in public places, recent healthcare contact and injecting in groups of three or more and SSTI.  23 
The collective data indicate the establishment of a successful clade of CA-MRSA (dubbed the “Bristol clade”) 24 
associated with colonisation and infection among Bristol’s PWID population. The data suggest that there has been 25 
ongoing circulation and transmission within the PWID community over several years.  More specifically, hierarchical 26 
clustering and phylogenetic analyses showed evidence of clonal expansion of an ST5-MRSA-IVg clade among PWID in 27 
10 
Bristol between 2012 and 2017 (Figure 1) indicating an association with this genotype and PWID risk group. This 1 
contrasts with the genetic heterogeneity observed among the non-PWID UHB admission screening samples which 2 
belonged to six different MLST-CCs. In addition, the Bristol clade is distinct from the dominant HA-MRSA strain 3 
circulating in the UK (CC22-SCCmecIVh; EMRSA-15) and the epidemiological and genomic data identify it as a PVL-4 
negative community-associated type of MRSA[9]. Given our knowledge of MRSA epidemiology in hospitals in 5 
England (currently dominated by CC22-IVh and CC5-IVc), we regard the ST5-IVg clone identified among PWID as 6 
being a community-like MRSA because we have rarely noted it in hospitalised patients and the bacteraemia cases 7 
observed in PWID are community onset (occurring <48h following admission to hospital).  As has been noted for 8 
other MRSA lineages and ecological niches, we hypothesise that representatives of this clade have evolved and 9 
increased in fitness through adaptation to particular settings and populations [36].  Representatives of the Bristol 10 
clade were identified in 11 individuals where there was no evidence of injecting drug use (including seven pre-11 
admission screening swabs from Bristol and four clinical infections occurring in geographically distinct regions in 12 
England and Wales). Other risk factors such as contact with PWID, homelessness or alcohol abuse may account for 13 
some/all of these cases. This is supported by evidence that networks of PWID can operate as reservoirs of infection 14 
with significant links to the general population [37].  This may provide evidence that this lineage is infiltrating wider 15 
population networks. An alternative explanation could be that a rare strain of MRSA from the general population has 16 
entered and spread through the Bristol PWID population.  The study is unable to provide a definitive answer as to 17 
the source of this strain.  18 
 The data indicate an association between the presence of a specific lineage of MRSA among PWID and developing 19 
an invasive infection. This is supported by the smaller number or absence of invasive samples belonging to other 20 
lineages (data not shown). This association could be attributable to adaptation or tropism within this MRSA strain or 21 
the epidemiological characteristics of the affected groups, such as injecting practices [36].   22 
A major limitation of this study is the sample size as it provided insufficient power to perform multivariable analysis 23 
and some of the associations could be subject to confounding.  This issue was anticipated and the study was 24 
designed to provide a baseline from which further work could be conducted. Moreover, as there is no sampling 25 
frame for this population, we used a non-random sampling method to recruit participants. To mitigate this issue we 26 
used a quota based approach to ensure the sample was representative of the known of PWID population in Bristol. 27 
The age and sex distribution of our sample was similar to the PWID population engaged with the extensive NSP in 28 
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Bristol, that involves both fixed and mobile programmes, as previously measured by BDP in 2015 (data not shown).  1 
The cross sectional design was not able to estimate incidence or rule out reverse causation between colonisation 2 
and risk factors. Finally PHE reference laboratory holds data on PWID status however this often poorly completed 3 
this could result in misclassification of non-PWID samples.  4 
Taken together, the high colonisation prevalence, establishment of a successful clone of CA-MRSA within the PWID 5 
population, possible dissemination to the general population and the high number of invasive infections within a 6 
specific vulnerable group, we believe there is sufficient evidence for public health action. Currently we are not aware 7 
of any specific guidance in Europe or worldwide for the management of MRSA in PWID. Previous outbreaks have 8 
targeted enhanced wound care and basic hand hygiene interventions alongside improved access to healthcare; 9 
although the effectiveness of these measures remains untested [38]. Ideally any intervention should be aimed 10 
towards targeting not only MRSA but bacterial infections in general. A more holistic approach is desirable 11 
particularly in light of outbreaks of invasive group A streptococci (iGAS) infections affecting PWID populations in the 12 
United Kingdom (2016 and 2017) and in Canada (2008). These were caused by the emergence of unusual strain types 13 
resulting in a substantial number of cases and could not be traced to a source [39–41]. A general approach is also 14 
likely to be more effective than suppression therapy on its own as it is widely recognised that MRSA decolonisation 15 
therapy (nasal cream and body wash) can be ineffective [42]. Apparent failure of eradication can be multi-factorial 16 
and, from our data, we do not know what treatment regimen was used and whether it was adhered to or not.  17 
More broadly, a range of harm reduction measures have been shown to effectively reduce the risk of bacterial 18 
infections among PWID, such as  provision of advice and education in good hygienic practices and basic infection 19 
prevention control [43]. Providing training in safe injection techniques, including cleaning of the injection site, can 20 
also  lower bacterial infection risk [44, 45]. There remains the need for upstream interventions, such as providing 21 
harm reduction resources, supervised injecting facilities and opioid substitution therapy, as these are excellent 22 
methods to reduce the overallnumber of infections among PWID [43, 46–49]. The results of this study have been 23 
used to improve the post infection review process and develop a pilot with planned evaluation for universal supply 24 
for of Chlorhexidine wipes to PWID through NSP. The findings from this study provide information to help inform the 25 
development of targeted interventions such as community-based screening , health promotion messaging, wound 26 
care, skin cleaning advice and suppression therapy with personal and environmental decontamination (washing 27 
clothes and bedding) [38, 50].   28 
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From a wider perspective, molecular epidemiological initiatives locally, nationally and internationally should be 1 
encouraged to further our understanding of clonal shifts in MRSA not only within “at risk” groups such as PWID, but 2 
across all healthcare sectors. Such studies should be prospective in nature and utilise a social network approach to 3 
identify high risk communities and factors associated with MRSA infection. There is a need to develop and evaluate 4 
the feasibility of community- and hospital-based interventions to combat MRSA in PWID. Current issues centre on 5 
the complexity of managing PWID as inpatients, adherence to treatment and re-acquisition of MRSA within the 6 
community. These groups have frequent hospital contact which could negatively impact on local infection control for 7 
MRSA; therefore increasing awareness of local medical staff is vital to promote screening and the appropriate 8 
prescribing of suppression treatment to MRSA-positive PWID as is widely recommended on admission to hospital.   9 
In conclusion this study details the worrying emergence of a CA-MRSA clone within Bristol’s PWID population. This 10 
clone is circulating within the community and is responsible for a large number of invasive infections in PWID. 11 
Surveillance and further research are required locally, nationally and internationally to examine the epidemiology of 12 
this clone and identify areas/people at risk. Public health action is required to mitigate this on-going threat and 13 
protect PWID from MRSA and other bacterial infections.  14 
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1 
Table 1: Univariable analysis of factors associated with MRSA in colonisation, Neg = negative for MRSA colonisation, Pos = positive for 
MRSA colonisation.  
Variable Value Neg %  Pos % Total OR 95% CI  
Skin and soft tissue 
infection in the past year 
No 96 94.1% 6 5.9% 102 Ref-  - 
Yes 40 85.1% 7 14.9% 47 2.8 0.89 to 8.85 
Most frequently injecting 
location 
House own/friend 75 94.9% 4 5.1% 79 Ref- -  
Hostel, squat, other 44 91.7% 4 8.3% 48 1.7 0.41 to 7.16 
OutsidePublic 
places 17 77.3% 5 22.7% 22 5.5 1.34 to 22.73 
Hospital contact past 
month 
No 107 94.7% 6 5.3% 113 Ref- -  
Yes 29 80.6% 7 19.4% 36 4.3 1.34 to 13.8 
Homeless past year No 80 95.2% 4 4.8% 84 Ref- -  
Yes 56 86.2% 9 13.8% 65 3.2 0.94 to 10.96 
Groin inject in the past 
month 
No 72 96.0% 3 4.0% 75 Ref- -  
Yes 64 86.5% 10 13.5% 74 3.8 0.99 to 14.23 
Ever experienced a DVT 
co-morbidity 
No 102 93.6% 7 6.4% 109 Ref- -  
Yes 34 85.0% 6 15.0% 40 2.6 0.81 to 8.18 
Frequently inject in 
groups 
Own 79 94.0% 5 6.0% 84 Ref- -  
Less than 3 54 91.5% 5 8.5% 59 1.5 0.4 to 5.3 
Three or more 3 50.0% 3 50.0% 6 15.8 2.51 to 99.28 
Previous MRSA Infection 
No previous 
infection 119 94.4% 7 5.6% 126 Ref  -  
> 3 months ago 12 85.7% 2 14.3% 14 2.8 0.53 to 15.2 
< 3 months ago 5 55.6% 4 44.4% 9 13.6 2.98 to 62.17 
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1 
Table 3: comparison of colonised persons within clades in terms of their epidemiological metadata.  
Characteristic Clade A Clade B Clade C 
Hospital contact 3  3  0  
Groin injecting 2  3  3  
Homelessness 3  2  3  
Infection at injection site 3  1  2  
MRSA infection 1  2  0  
Total 4  3  4  
 
 
1 
Table 2: Summary statistics associated with the predictive nature of each clinical assessment group. 
Group Value Neg Pos OR 95% CI  P Sens Spec ROC PPV 
Group 1 No 70 1 Ref - - - - - - 
Yes 66 12 12.57 1.77 to 551.65 0.004 92.3% 51.5% 0.72 15.4% 
Group 2 No 68 1 Ref - - - - - - 
Yes 68 12 11.86 1.67 to 520.34 0.005 92.3% 50.0% 0.71 15.0% 
Group 3 No 78 2 Ref - - - - - - 
Yes 58 11 7.31 1.51 to 70.36 0.008 84.6% 57.4% 0.71 15.9% 
Group 4 No 75 2 Ref - - - - - - 
Yes 61 11 6.69 1.38 to 64.35 0.011 84.6% 55.1% 0.70 15.3% 
Total 
  136 13 NA NA NA NA NA NA NA 
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Figure 1: Maximum-likelihood phylogenetic tree based on SNPs in the core genome of 71 ST5-
MRSA including: 24 bacteraemia and 12 carriage isolates from PWID in Bristol, 8 carriage (pre-
admission screening) isolates from patients in Bristol and 27 temporally-related, geographically 
dispersed isolates from PHE national reference laboratory archives; reference genome N315 
(NC002745). SCCmec types are denoted on the branches. Black squares indicate PWID status 
and presence of genetic markers associated with particular resistance traits. Isolate labels are 
coloured according to geographic region. Clinical groups comprised bacteraemia infection (n = 
44) , non-bacteraemia infection (n = 12) and carriage (n= 15 ). A, B, C designation denotes sub-
clusters within Bristol clade at 150 SNP threshold. Scale of branch distance represents 
approximately 140 SNPs.
